Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

Clinical pathology selected abstracts

June 2024—In today’s health care environment, clinical laboratories increasingly must focus on test optimization, or generating quality patient care in a timely manner while controlling costs. A metric that can assist with test optimization is turnaround time (TAT), the reduction of which can lead to earlier diagnosis and treatment. Conducting assays in house is one way to potentially reduce TAT. Laboratories often use test volume and the cost of reagents, equipment, and personnel to determine the benefit of bringing an assay in house. However, it is important not to overlook the impact and costs that extend beyond the laboratory with regard to patient care and potential savings from improved care.

Anatomic pathology selected abstracts

June 2024—Neuroendocrine neoplasms can arise in a variety of anatomic sites, including the gastrointestinal tract, pancreas, and lung. The authors conducted a study in which they examined the diagnostic utility of S100 protein expression by IHC. They reported on the expression of S100 protein in a tissue microarray composed of 919 primary and metastatic neuroendocrine neoplasms from 548 patients. S100 protein is commonly used by laboratories to identify neural and melanocytic neoplasms. It is occasionally used in the workup of neuroendocrine neoplasms when the diagnosis of paraganglioma is being considered.

Molecular pathology selected abstracts

June 2024—Somatic mutations in SETBP1 occur in a variety of myeloid malignancies, including myelodysplastic/myeloproliferative neoplasms, typically as secondary events during oncogenesis. However, whether SETBP1 alterations can serve as an initiating event for myeloid neoplasia and what other factors may influence the phenotype of SETBP1-mutated myeloid neoplasms remains unclear. To determine if SETBP1 mutations can initiate leukemia in vivo, the authors generated a mouse model expressing mutated SETBP1 in hematopoietic tissue. They reported that SETBP1G870S-mutated mice developed a chronic myeloid disorder with massive hepatosplenomegaly, myelofibrosis, atypical megakaryocytes, and granulocytic hyperplasia without granulocytic or erythroid dysplasia. SETBP1G870S precursors showed significant alterations in the transcriptional programs of differentiating hematopoietic cells, promoting granulocytic/monocytic differentiation while suppressing erythroid differentiation.

Q&A column

June 2024
Q. What are the requirements for correcting an automated white blood cell (WBC) count for the presence of megakaryocytes? Is there a formula for correcting it for megakaryocytes, as there is for the presence of nucleated red blood cells (nRBCs)? Read answer.
Q. Are there guidelines on how often a patient should be monitored for a blood transfusion reaction? Should reactions be monitored as frequently as vital signs? Read answer.

Newsbytes

June 2024—Fairness, like so many principles, is subjective. Yet that is not deterring a growing number of medical informaticists and others interested in health care technology from advocating to incorporate fairness into machine learning algorithms to combat bias.

Put It on the Board

June 2024—The Food and Drug Administration in May approved the two HPV self-collection approaches from Roche and BD.

Climate of concern over fungal infections

May 2024—If anything keeps Arturo Casadevall, MD, PhD, lying awake at night, it’s the frogs. And the bats. Also, the patients (relatively few, at least for now) who are affected by invasive fungal diseases. Dr. Casadevall is a microbiologist and infectious diseases expert in the Johns Hopkins Division of Infectious Diseases, Department of Medicine, and the Bloomberg School of Public Health, where he’s a professor of medicine and chairs the Department of Molecular Microbiology and Immunology. In his waking hours, he looks deeply and broadly at the natural world and how the disturbing growth of fungal infections might impact the medical world. Though the arrows haven’t hit the bull’s-eye, they seem to be flying in that direction, says Dr. Casadevall, who has written widely on this topic, including “Immunity to Invasive Fungal Diseases.” In a recent interview with CAP TODAY, Dr. Casadevall spoke about how he and others in the field are thinking about how medicine might respond to this potential threat.

Core lab efficiencies in monoclonal gammopathy testing

May 2024—Many laboratories have brought order to chaos in test ordering by launching initiatives to do so, for cost and staff savings and patient care benefits. TriCore is one—it set its sights on orders for monoclonal gammopathies.

Lupus anticoagulant—proficiency test and preanalytics

May 2024—What is a lupus anticoagulant (LA)? LA is somewhat of a misnomer. Many patients with this condition do not have systemic lupus erythematosus (SLE) and usually do not bleed. However, the in vitro phenomenon was originally described in patients with SLE, as well as other autoimmune disorders—thus use of the term “lupus,” and this does often lead to prolonged in vitro coagulation testing—thus use of the term “anticoagulant.”

MARKETPLACE

TRENDING